The presentation introduces the Co-Dx PCR platform and smartphone interface and discusses how Co-Dx is harnessing AI to minimize user error and improve outcomes in real-time point-of-care testing.
Co-Diagnostics Inc (Co-Dx) is presenting its move to portable PCR diagnostics to address evolving point-of-care needs at the Point-of-Care Testing 2025 Exhibition and Conference, being held Dec 8-9 in Boston.
The presentation, titled “Exploring the Promise of Portable, Cloud-Connected PCR Diagnostics,” will introduce the company’s upcoming Co-Dx PCR platform and smartphone interface and discuss how Co-Dx is harnessing AI to minimize user error and improve outcomes in real-time point-of-care testing.
The Point-of-Care Testing 2025 conference brings together industry leaders and healthcare innovators to examine advances in diagnostic testing and clinical strategies. Conference topics include point-of-care diagnostic trends, mobile testing platforms, AI integration in diagnostics, and testing solutions for infectious and chronic disease management.
Co-Diagnostics develops molecular diagnostic technologies for detecting and analyzing nucleic acid molecules, including DNA and RNA. The company uses its proprietary technology to design tests for its Co-Dx PCR platform and to identify genetic markers for applications beyond infectious disease testing.
The Co-Dx PCR platform, including all associated tests and software, remains subject to US Food and Drug Administration and regulatory review and is not currently available for sale.
ID 187071041 © Phuttaphat Tipsana | Dreamstime.com
